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Scott Syndrome is a very rare inhibited bleeding disorder characterised by an isolated deficit 
in procoagulant activity in platelets and other blood cells, caused by a lack of 
phosphatidylserine (PS) exposure following activation.1,2 It results from mutations in ANO6, 
which encodes the phospholipid scramblase protein, TMEM16F.3  
 
Platelet PS exposure in coagulation 
Negatively charged phospholipids – particularly PS, but also phosphatidylethanolamine (PE) 
– facilitate Ca2+-dependent binding of the γ-carboxyglutamate (Gla) domains of vitamin K-
dependent coagulation factors (factors II [prothrombin], VII, IX and X) to phospholipid 
membranes.4  This promotes the formation of the tenase and prothrombinase complexes on 
PS-exposing platelets. PS-exposing platelets also enhance the activities of these complexes 
by nearly 1000-fold.5  Platelet PS exposure therefore plays a central role in coagulation.  
 
Scott Syndrome 
Patients present with a mild-to-moderate bleeding phenotype, suffering from post-operative 
or post-partum haemorrhage but without easy bruising or excessive bleeding from superficial 
cuts.2,6,7 Only 6 cases of Scott Syndrome have been reported to date,2,6–9 though it may be 
underdiagnosed due to its relatively mild clinical presentation until a significant haemostatic 
challenge and lack of routine diagnostic test. Scott Syndrome patients have prolonged 
prothrombin times and high residual plasma prothrombin levels, but a definitive diagnosis 
requires measurement of platelet PS exposure by flow cytometry. After diagnosis, 
management involves appropriate platelet transfusions during procedures to prevent 
excessive blood loss.2,10 
The original patient, Mrs Scott (MS), had deficient platelet procoagulant activity but all other 
platelet functions, including adhesion, aggregation and secretion, were normal.2 The 
description of a second patient (FS) and her family indicated that Scott Syndrome was a 
genetic condition following an autosomal recessive inheritance pattern.6 FS and her two 
older sisters, who had both died from post-partum haemorrhage, were suggested to be 
homozygous for the Scott mutation. Platelets from two of FS’ asymptomatic children 
displayed intermediate procoagulant activity between those of their mother and controls, 
suggesting they were heterozygous for the Scott mutation. MS’ asymptomatic mother, father 
and son also showed intermediate platelet prothrombinase activity,11 again indicating an 
autosomal recessive trait.  It may be a coincidence that all of the small number of Scott 
patients described to date are female, but the 3 patients known to have had children (MS, 
FS, VW7) all suffered with post-partum haemorrhage, perhaps illustrating the particular 
importance of platelet-based coagulation post-partum. 
 
Identification of ANO6 
Scott Syndrome platelets were originally described as lacking platelet factor 3, leading to 
reduced factor Va and Xa binding to the surface of activated platelets12 and consequent 
reduced subendothelial fibrin deposition.13 Platelet factor 3 was later identified as the 
exposure of the negatively-charged phospholipid PS on the surface of activated platelets.1 
Studies on resealed RBC ghosts showed that the Scott Syndrome defect was in an intrinsic 
membrane component responsible for PS exposure.14  
PS is normally restricted to the inner leaflet of the plasma membrane by inward ‘flippase’ 
activity (Fig. 1). Procoagulant platelet stimuli, such as dual stimulation with collagen and 
thrombin, or a Ca2+ ionophore, trigger a large, sustained increase in cytosolic Ca2+. This 
inhibits flippase activity and activates a ‘scramblase’ activity – bidirectional, non-selective 
movement of phospholipids, leading to loss of membrane asymmetry. Flippase activity is 
unaffected in Scott Syndrome patients but the scramblase activity is defective.15,16 As a 
result, PS exposure is almost completely abolished in Scott Syndrome platelets following 
stimulation.1 Platelet microparticle release, which requires PS exposure, is also abolished.17 
Procoagulant platelets resemble necrotic cells, with a diluted cytoplasm, few remaining 
organelles and rapid swelling into large ‘balloon’-like structures.18,19 Procoagulant ballooning 
is also diminished in Scott Syndrome platelets.20,21  
Scott Syndrome red blood cells (RBCs) also display defective PS exposure, microparticle 
release and echinocytosis.14 Immortalised Scott Syndrome B-lymphocytes also have 
impaired PS exposure and procoagulant activity.22  
Two proteins were previously proposed to be the phospholipid scramblase: PLSCR1 and 
ABCA1. PSLCR1 was initially described as a putative scramblase in RBCs.23 However, 
PSLCR1 mRNA and protein 24 levels, and later sequence,25 were all normal in Scott 
Syndrome patients (MS and FS). Furthermore, PSLCR1-/- mice have normal haemostasis 
and platelet and RBC PS exposure,26 excluding PSLCR1.  
A missense mutation in the ABCA1 gene was identified in a third Scott patient (VW) 
(c.6064G>A (ABCA1 R1925Q)) 27 which reduced its expression in lymphocytes. This 
mutation, however, has not been found in any other Scott Syndrome patients and ABCA1 is 
now known to play a role in cholesterol efflux.28 ABCA1 mutations cause Tangier disease, 
patients of which expose normal platelet PS.29,30  
TMEM16F was eventually identified as the scramblase protein following a cell-based screen 
in which TMEM16F mutants displayed constitutive PS exposure.3 ANO6, which encodes 
TMEM16F, was first described in silico in 2004.31 It is a member of the anoctamin family, so 
called as they were predicted to encode proteins with 8 transmembrane domains. The 
publication of the mouse TMEM16F structure, however, confirmed that it has 10 
transmembrane domains.32 The properties of the ANO6 gene and TMEM16F protein are 
listed in Table 1. Four Scott Syndrome patients have been sequenced, each with mutations 
in ANO6 (Table 2)3,33,34. Notably, each known mutation results in a complete absence of 
expression of TMEM16F in patients. It is not known whether other mutations exist that affect 
TMEM16F function or reduce rather than abolish its expression, but it is plausible that 
asymptomatic individuals carry variants of the TMEM16F protein that affect procoagulant 
scramblase activity. 
Scott Syndrome platelets show additional differences beyond TMEM16F. A proteomic 
screen of a Scott Syndrome patient’s platelets (VW) found differential expression of 134 
proteins, with aquaporin 1 expression being particularly strongly upregulated, and increased 
protein phosphorylation following stimulation.35 Further differences in tyrosine 
phosphorylation have also been determined between Scott Syndrome platelets (MS) and 
controls.16 The ABCA1 mutation in VW27 shows that other mutations are present that may 
contribute to the clinical presentation.   
 
Animal models of Scott Syndrome 
Several animal models support the identification of ANO6 mutations as causative of Scott 
Syndrome. Four different viable Ano6-/- mouse knockout lines have been described20,36–38. 
Their phenotypes slightly differ, but, as in Scott Syndrome platelets, agonist-induced PS 
exposure is substantially reduced. Where measured, arterial thrombosis is also inhibited. 
The reduction in PS exposure is not complete, suggesting that another scramblase or 
mechanism of PS exposure may exist but plays a much lesser role in thrombosis. It is 
particularly striking that the bleeding phenotype of the four viable Ano6-/-  mouse lines differ 
considerably ranging from no difference in tail bleeding time compared to wild type mice,37 
most similar to Scott Syndrome patients, to significantly prolonged bleeding times20,38. A 
canine Scott syndrome also occurs in German Shepherd dogs,39 also due to a mutation in 
ANO6.40 In these Scott Syndrome dogs, bleeding time is normal.  
Ano6-/- mouse models have implicated TMEM16F in many other processes including pain 
behaviour, mucus production, bone mineralisation and preventing immune cell 
overactivation.41–44 TMEM16F is also implicated in entry of enveloped viruses, including 
Ebola and HIV.45,46 Due to the small number of Scott Syndrome patients it is not known if 
TMEM16F plays similar roles in human physiology.  
 
Overall, although Scott Syndrome is a very rare bleeding disorder, its description has 
contributed to the understanding of platelet procoagulant activity and highlights the 
importance of platelet-based coagulation in acute haemostatic challenges and thrombosis.  
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Figure 1: TMEM16F in platelet procoagulant activity. (A) In unactivated platelets, 
phosphatidylserine (PS) is restricted to the inner leaflet of the plasma membrane by flippase 
activity. The scramblase, TMEM16F (encoded by ANO6), is not active. In response to a 
high, sustained increase in cytosolic Ca2+ concentration, the flippase is inactivated and 
TMEM16F is activated. TMEM16F catalyses bidirectional movement of PS and other 
phospholipids, resulting in loss of plasma membrane asymmetry. (B) shows the response at 
a cellular level. Strong stimuli, such as collagen + thrombin or Ca2+ ionophores, trigger PS 
exposure, which promotes thrombin generation, rapid swelling (sometimes called 
‘ballooning’) and release of PS-exposing microparticles. Each of these responses is deficient 
in platelets from patients with Scott Syndrome.  
 
Table 1: Details of ANO6 and its protein product, TMEM16F 
 
Human Mouse Dog 
Gene name ANO6  Ano6 ANO6 
Location 12q12 
Chromosome 12 
Chromosome 15 Chromosome 27 
Base pairs  224,418 183,908 184,366 
Exons 20 20 22 
 
TMEM16F Tmem16f TMEM16F 
Amino acids 910 911 910 
Transmembrane domains 10 10 10* 
* presumed, based on sequence similarity 
 
Patient References ANO6 Mutation(s) 
MS   Original patient description: Weiss et al., 1979 (Ref 2) 
Sequencing: Suzuki et al., 2010 (Ref 3) 
• Homozygous G>T mutation at a splice acceptor site in intron 12. Predicted to 
lead to the skipping of exon 13 and a frameshift in exon 14 causing premature 
termination.  
• Each of MS’ asymptomatic parents were heterozygous for the G>T mutation. 
VW  Original patient description: Parry et al., 1980 (Ref 8) 
Diagnosis of Scott Syndrome: Munnix et al., 2003 
(Ref 5) 
Sequencing: Castoldi et al., 2011 (Ref 28) 
• VW was a compound heterozygote with 2 mutations in ANO6. 
o A G>A mutation at the first nucleotide of intron 6 disrupting the donor 
splice site consensus sequence, which leads to the skipping of exon 6; 
predicted to cause in-frame deletion of 38 amino acids at the N-terminal 
cytoplasmic tail.  
o An insertion in exon 11 (c.1219insT), predicted to cause a frame shift and 
premature termination.  
FS  
 
Original patient description: Toti et al.,1996 (Ref 4) • No sequence available  
2 siblings  Original patient description: Halliez et al., 2015 (Ref 
6) 
• Sequencing: Boisseau et al., 2016 (Ref 27) 
• Both siblings were compound heterozygous 
o A nonsense variant c.889C>T in exon 8 leading to premature termination.  
o A deletion of exons 1-10 on the other allele.  
Brazilian 
patient  
• Original patient description: Flores-Nascimento et al., 
2012 (Ref 7) 





Original Description: Brooks et al., 2012 (Ref 34)  
• Sequencing: Brooks et al., 2015 (Ref 35) 
• A G>A mutation at the exon 16 splice donor site. 
• All affected GSDs were homozygous (AA), and all carriers were heterozygous 
(AG).  
 
Table 2: Known ANO6 mutations in patients with Scott Syndrome, in order of first report. German Shepherd Dogs with Scott Syndrome are 
included for comparison. For all mutations so far described, the effect is likely to be complete loss of TMEM16F protein expression.  
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